Rafferty Asset Management
NRIX icon

Rafferty Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Rafferty Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Sell
68,360
-81,163
-54% -$1.38M ﹤0.01% 685
2026
Q1 		$2.32M Buy
149,523
+59,008
+65% +$978K 0.01% 575
2025
Q4 		$1.72M Sell
90,515
-1,930
-2% -$27.7K 0.01% 684
2025
Q3 		$854K Buy
92,445
+16,722
+22% +$174K ﹤0.01% 826
2025
Q2 		$862K Sell
75,723
-34,359
-31% -$371K ﹤0.01% 787
2025
Q1 		$1.31M Sell
110,082
-6,104
-5% -$102K 0.01% 681
2024
Q4 		$2.19M Buy
116,186
+22,593
+24% +$518K 0.01% 628
2024
Q3 		$2.1M Sell
93,593
-43,723
-32% -$990K 0.01% 623
2024
Q2 		$2.87M Sell
137,316
-74,109
-35% -$1.15M 0.01% 542
2024
Q1 		$3.11M Buy
+211,425
New +$2.27M 0.01% 575
2023
Q4 		– Sell
-98,839
Closed -$777K – 1090
2023
Q3 		$777K Sell
98,839
-15,649
-14% -$143K ﹤0.01% 853
2023
Q2 		$1.14M Sell
114,488
-25,659
-18% -$262K 0.01% 788
2023
Q1 		$1.24M Sell
140,147
-24,932
-15% -$260K 0.01% 743
2022
Q4 		$1.81M Buy
165,079
+34,170
+26% +$412K 0.02% 607
2022
Q3 		$1.71M Buy
130,909
+59,860
+84% +$947K 0.02% 546
2022
Q2 		$900K Sell
71,049
-75,231
-51% -$853K 0.01% 683
2022
Q1 		$2.05M Buy
146,280
+55,574
+61% +$986K 0.01% 594
2021
Q4 		$2.63M Buy
90,706
+31,840
+54% +$965K 0.01% 573
2021
Q3 		$1.76M Sell
58,866
-19,824
-25% -$612K 0.01% 676
2021
Q2 		$2.09M Buy
78,690
+10,863
+16% +$319K 0.01% 675
2021
Q1 		$2.11M Buy
+67,827
New +$2.57M 0.01% 606

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rafferty Asset Management's NRIX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Nurix Therapeutics (NRIX) stake by 54% in Q2 2026, selling an estimated $1.38M and leaving 68,360 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Rafferty Asset Management first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $3.11M in Q1 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Rafferty Asset Management held 68,360 shares of Nurix Therapeutics worth $1.66M as of Q2 2026.
  • Rafferty Asset Management sold 81,163 Nurix Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Nurix Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #685 holding.
  • Rafferty Asset Management first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Rafferty Asset Management's Nurix Therapeutics position peaked at $3.11M in Q1 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.